Daisuke Yamada

Dr. Daisuke Yamada


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2021 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
AMAkihiro Miura
Akihiro Miura
DYDaisuke Yamada
Daisuke Yamada
MNMasahiro Nakamura
Masahiro Nakamura
STShuta Tomida
Shuta Tomida
DSDai Shimizu
Dai Shimizu
Takeshi TakaradaTakeshi Takarada
Takeshi Takarada

10 September 2018 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
DYDaisuke Yamada
Daisuke Yamada
KFKoichi Fujikawa
Koichi Fujikawa
KKKenji Kawabe
Kenji Kawabe
TFTakuya Furuta
Takuya Furuta
MNMitsutoshi Nakada
Mitsutoshi Nakada
Takeshi TakaradaTakeshi Takarada
Takeshi Takarada

26 October 2022 in STAR Protocols
Verified
Journal Article
Open access
TTTomoka Takao
Tomoka Takao
DYDaisuke Yamada
Daisuke Yamada
Takeshi TakaradaTakeshi Takarada
Takeshi Takarada
Here, we present a protocol for the selective differentiation of human pluripotent stem cells mimicking human developmental processes into expandable PRRX1+ limb-bud mesenchymal (ExpLBM) cells. This approach enables expansion through serial passage while maintaining capacity for chondrogenic differentiation.

1 July 2006 in Surgery
Verified
Journal Article
Closed access
YOYasuhiro Ogura
Yasuhiro Ogura
KMKazuhiro Mizumoto
Kazuhiro Mizumoto
MTMasao Tanaka
Masao Tanaka
KOKenoki Ohuchida
Kenoki Ohuchida
MMMitsuhiko Murakami
Mitsuhiko Murakami
ENEishi Nagai
Eishi Nagai

Verified
Journal Article
Open access
PDF file
SHShojiro Hanaki
Shojiro Hanaki
DYDaisuke Yamada
Daisuke Yamada
TTTomoka Takao
Tomoka Takao
RIRyosuke Iwai
Ryosuke Iwai
Takeshi TakaradaTakeshi Takarada
Takeshi Takarada
The limited capacity of articular cartilage for self-repair is a critical challenge in orthopedic medicine. Here, we aimed to develop a simplified method of generating chondrocyte particles from human-induced pluripotent stem cell-derived expandable limb-bud mesenchymal cells (ExpLBM) using a cell self-aggregation technique (CAT). ExpLBM cells were induced to form chondrocyte particles through a stepwise differentiation protocol performed on a CAT plate (prevelex-CAT®), which enables efficient and consistent production of an arbitrary number of uniformly sized particles. Histological and immunohistochemical analyses confirmed that the generated chondrocyte particles expressed key cartilage markers, such as type II collagen and aggrecan, but not hypertrophic markers, such as type X collagen. Additionally, when these particles were transplanted into osteochondral defects in rats with X-linked severe combined immunodeficiency, they demonstrated successful engraftment and extracellular matrix production, as evidenced by Safranin O and Toluidine Blue staining. These data suggest that the plate-based CAT system offers a robust and scalable approach to produce a large number of chondrocyte particles in a simplified and efficient manner, with potential application to cartilage regeneration. Future studies will focus on refining the system and exploring its clinical applications to the treatment of cartilage defects.

Verified
Journal Article
Open access
PDF file
DYDaisuke Yamada
Daisuke Yamada
TTTomoka Takao
Tomoka Takao
MNMasahiro Nakamura
Masahiro Nakamura
TKToki Kitano
Toki Kitano
ENEiji Nakata
Eiji Nakata
Takeshi TakaradaTakeshi Takarada
Takeshi Takarada
Stem cell-based therapies and experimental methods rely on efficient induction of human pluripotent stem cells (hPSCs). During limb development, the lateral plate mesoderm (LPM) produces limb-bud mesenchymal (LBM) cells that differentiate into osteochondroprogenitor cells and form cartilage tissues in the appendicular skeleton. Previously, we generated PRRX1-tdTomato reporter hPSCs to establish the protocol for inducing the hPSC-derived PRRX1+ LBM-like cells. However, surface antigens that assess the induction efficiency of hPSC-derived PRRX1+ LBM-like cells from LPM have not been identified. Here, we used PRRX1-tdTomato reporter hPSCs and found that high pluripotent cell density suppressed the expression of PRRX1 mRNA and tdTomato after LBM-like induction. RNA sequencing and flow cytometry suggested that PRRX1-tdTomato+ LBM-like cells are defined as CD44high CD140Bhigh CD49f−. Importantly, other hPSC lines, including four human induced pluripotent stem cell lines (414C2, 1383D2, HPS1042, HPS1043) and two human embryonic stem cell lines (SEES4, SEES7), showed the same results. Thus, an appropriate cell density of hPSCs before differentiation is a prerequisite for inducing the CD44high CD140Bhigh CD49f− PRRX1+ LBM-like cells.